Evotec SE (NASDAQ:EVO - Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 38,169 shares traded hands during trading, a decline of 24% from the previous session's volume of 49,954 shares.The stock last traded at $4.39 and had previously closed at $4.22.
Analyst Ratings Changes
EVO has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of Evotec in a report on Thursday, November 7th. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and lowered their price target for the company from $8.70 to $3.80 in a report on Monday, October 7th.
Get Our Latest Stock Analysis on Evotec
Evotec Stock Down 4.6 %
The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The company's fifty day simple moving average is $4.47 and its two-hundred day simple moving average is $4.04.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC acquired a new position in shares of Evotec in the 3rd quarter valued at about $104,000. Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the 3rd quarter valued at about $512,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after buying an additional 602,858 shares during the period. 5.81% of the stock is owned by institutional investors and hedge funds.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
